|
Name
of entity
|
|
pSivida
Limited
|
|
ABN
|
Quarter
ended (“current quarter”)
|
|
|
78
009 232 026
|
30
September 2006
|
|
Cash
flows related to operating activities
|
Current
quarter
$A’000
|
Year
to date
(3
months)
$A’000
|
|
|
1.1
|
Receipts
from customers
|
192
|
192
|
|
1.2
|
Payments
for (a)
staff costs
(b) advertising and marketing
(c) research and development
(d) leased assets
(e) other working capital
|
(1,146)
-
(3,876)
-
(3,156)
|
(1,146)
-
(3,876)
-
(3,156)
|
|
1.3
|
Dividends
received
|
-
|
-
|
|
1.4
|
Interest
and other items of a similar nature received
|
53
|
53
|
|
1.5
|
Interest
and other costs of finance paid
|
(330)
|
(330)
|
|
1.6
|
Income
taxes paid
|
-
|
-
|
|
1.7
|
Other
|
-
|
-
|
|
Net
operating cash flows
|
(8,263)
|
(8,263)
|
|
|
Current
quarter
$A’000
|
Year
to date
(3
months)
$A’000
|
||
|
1.8
|
Net
operating cash flows (carried forward)
|
(8,263)
|
(8,263)
|
|
Cash
flows related to investing activities
|
|||
|
1.9
|
Payment
for acquisition of:
(a)
businesses (item 5)
(b)
equity investments
(c)
intellectual property
(d)
physical non-current assets
(e)
other non-current assets
|
-
-
-
(47)
-
|
-
-
-
(47)
-
|
|
1.10
|
Proceeds
from disposal of:
(a)
businesses (item 5)
(b)
equity investments
(c)
intellectual property
(d)
physical non-current assets
(e)
other non-current assets
|
-
-
-
-
-
|
-
-
-
-
-
|
|
1.11
|
Loans
to other entities
|
-
|
-
|
|
1.12
|
Loans
repaid by other entities
|
-
|
-
|
|
1.13
|
Other
|
-
|
-
|
|
Net
investing cash flows
|
(47)
|
(47)
|
|
|
1.14
|
Total
operating and investing cash flows
|
(8,310)
|
(8,310)
|
|
Cash
flows related to financing activities
|
|||
|
1.15
|
Proceeds
from issues of shares, options, etc.
|
-
|
-
|
|
1.16
|
Proceeds
from sale of forfeited shares
|
-
|
-
|
|
1.17
|
Proceeds
from borrowings
|
8,586
|
8,586
|
|
1.18
|
Repayment
of borrowings
|
(3,302)
|
(3,302)
|
|
1.19
|
Dividends
paid
|
-
|
-
|
|
1.20
|
Other -
other financing costs
|
(4,394)
|
(4,394)
|
|
Net
financing cash flows
|
890
|
890
|
|
|
Net
increase (decrease) in cash held
|
(7,420)
|
(7,420)
|
|
|
1.21
|
Cash
at beginning of quarter/year to date
|
15,447
|
15,447
|
|
1.22
|
Exchange
rate adjustments to item 1.20
|
(148)
|
(148)
|
|
1.23
|
Cash
at end of quarter
|
7,879
|
7,879
|
|
Current
quarter
$A'000
|
||
|
1.24
|
Aggregate
amount of payments to the parties included in item 1.2
|
254
|
|
1.25
|
Aggregate
amount of loans to the parties included in item 1.11
|
-
|
|
1.26
|
Explanation
necessary for an understanding of the transactions
|
|
|
1.1 1.2(a)
Staff
costs include consultants and directors’ fees paid by
pSivida.
1.2(c)
Research
and development costs include all expenditure incurred by pSiMedica
and
pSiOncology along with
research
and development costs incurred by pSivida Inc.
|
||
|
2.1
|
Details
of financing and investing transactions which have had a material
effect
on consolidated assets and liabilities but did not involve cash
flows
|
|
N/A
|
|
2.2
|
Details
of outlays made by other entities to establish or increase their
share in
businesses in which the reporting entity has an
interest
|
|
N/A
|
|
Amount
available
$A’000
|
Amount
used
$A’000
|
||
|
3.1
|
Loan
facilities
|
-
|
25,442
|
|
3.2
|
Credit
standby arrangements
|
-
|
-
|
|
Reconciliation
of cash at the end of the quarter (as shown in the
consolidated
statement of cash flows) to the related items in the
accounts
is as follows.
|
Current
quarter
$A’000
|
Previous
quarter
$A’000
|
|
|
4.1
|
Cash
on hand and at bank
|
1,358
|
3,922
|
|
4.2
|
Deposits
at call
|
6,521
|
11,524
|
|
4.3
|
Bank
overdraft
|
-
|
-
|
|
4.4
|
Other
(provide details)
|
-
|
-
|
|
Total:
cash at end of quarter (item
1.22)
|
7,879
|
15,447
|
|
|
Acquisitions
(Item
1.9(a))
|
Disposals
(Item
1.10(a))
|
||
|
5.1
|
Name
of entity
|
N/A
|
N/A
|
|
5.2
|
Place
of incorporation or registration
|
||
|
5.3
|
Consideration
for
acquisition
or disposal
|
||
|
5.4
|
Total
net assets
|
||
|
5.5
|
Nature
of business
|
||
|
1
|
This
statement has been prepared under accounting policies which comply
with
accounting standards as defined in the Corporations Act (except to
the
extent that information is not required because of note 2) or other
standards acceptable to ASX.
|
|
2
|
This
statement does give a true and fair view of the matters
disclosed.
|
|
1.
|
The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report. |
| 2. | The definitions in, and provisions of, AASB 107: Cash Flow Statements apply to this report except for the paragraphs of the Standard set out below. |
| · |
6.2-
reconciliation of cash flows arising from operating activities to
operating
profit or loss
|
| · |
9.2-
itemised disclosure relating to
acquisitions
|
| · |
9.4-
itemised disclosure relating to
disposals
|
| · |
12.1(a)-
policy for classification of cash
items
|
| · |
12.3-
disclosure of restrictions on use of
cash
|
| · |
13.1-
comparative information
|
| 3. | Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with. |